ViewsML announced it has raised $4.9 million in an oversubscribed seed funding round to accelerate commercialization of its virtual biomarker staining platform. The round was led by Wittington Ventures, with participation from Continuum Health Ventures and Mayo Clinic, alongside existing investors including RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund.
ViewsML is developing what it describes as the world’s first virtual biomarker library, using artificial intelligence to generate per-cell biomarker insights directly from pathology images without requiring traditional laboratory staining. The approach aims to transform immunohistochemistry from a lab-based process into a scalable software-driven workflow.
The company’s platform addresses a key bottleneck in drug development and diagnostics, where conventional staining processes can take days or weeks and require significant resources. By enabling virtual staining, ViewsML seeks to accelerate analysis timelines, reduce costs, and preserve limited tissue samples.
The new funding will be used to advance commercialization efforts, expand partnerships with healthcare and biopharma organizations, support clinical validation of its technology, and grow its engineering, scientific, and commercial teams.
ViewsML is already collaborating with pharmaceutical companies, hospitals, and diagnostic labs to deploy its technology across research and clinical use cases, including translational research, clinical trials, and precision medicine initiatives.
The investment reflects growing interest in AI-driven approaches to biomedical research and diagnostics, particularly those that can unlock value from existing datasets and improve the speed and scalability of analysis.
KEY QUOTES:
“Biomarkers are foundational to how we understand and treat disease, yet the way we measure them remains constrained by legacy approaches. ViewsML is redefining how biomarkers are measured and analyzed – unlocking a step-change in speed, scale, and accessibility across research and clinical settings. Virtual staining has the potential to accelerate workflows, lower costs, and unlock new applications across translational research, diagnostics, clinical trials and emerging areas such as neurodegenerative disease – driving faster insights and improved patient outcomes.”
Zeeshan Ali, Partner, Wittington Ventures
“We’re building the computational layer for next-generation diagnostics, and are excited to partner with Wittington Ventures and work with Mayo Clinic to accelerate that vision. This capital will enable us to fast-track our efforts to revolutionize immunohistochemistry. By building the world’s first virtual biomarker library, we’re going to empower scientists and clinicians to analyze biomarker staining in minutes rather than the traditional days or weeks.”
Kenneth To, CEO, ViewsML
